DGX SEC Filings

Quest Diagnostics Inc. (DGX) reported a solid financial performance for the second quarter and the first half of 2026, demonstrating robust top-line growth and improved profitability. Total net revenues increased by 10.2% for the quarter and 9.7% for the six-month period, primarily driven by a significant increase in volume within the Diagnostic Information Services (DIS) segment. This growth was bolstered by new relationships, including the collaborative lab solutions with Corewell Health and increased testing for Fresenius Medical Care. Despite some headwinds such as a slight decrease in revenue per requisition due to business mix, the company managed operating costs effectively, leading to an increase in operating income of 4.6% for the quarter and 9.4% for the year-to-date period. Net income attributable to Quest Diagnostics also saw substantial growth, rising by 13.4% for the quarter and 13.9% for the six months. The company also continued its focus on capital allocation, with increased share repurchases and dividend payments, reflecting confidence in its financial position and future prospects.

Quest Diagnostics Incorporated (DGX) has filed an 8-K report on July 23, 2026, to announce its financial results for the quarter ended June 30, 2026. The primary focus of this filing is the dissemination of these quarterly results, as detailed in the attached press release (Exhibit 99.1). Investors should refer to this press release for specific financial performance metrics, including revenue, earnings, and any forward-looking guidance provided by the company for the upcoming periods. While the 8-K itself is brief, indicating the press release contains the substance of the announcement, it serves as a formal notification to the market. The filing primarily confirms the release of Q2 2026 earnings and provides the official record for their disclosure. Investors are encouraged to review the accompanying press release for comprehensive details on the company's operational and financial condition, management's commentary, and any strategic updates.

Quest Diagnostics Inc. (DGX) filed an 8-K report on May 21, 2026, detailing the results of its 2026 Annual Meeting of Stockholders held on May 20, 2026. The primary focus of this filing is the voting outcomes on key corporate governance matters, including director elections and executive compensation. The company saw overwhelming support for its nominated directors, with all nominees being re-elected with substantial 'For' votes, indicating strong shareholder confidence in the current board leadership. Furthermore, shareholders approved the executive compensation as disclosed in the 2026 Proxy Statement through an advisory resolution, and also ratified the appointment of PricewaterhouseCoopers as the independent registered public accounting firm for the fiscal year 2026. Notably, a stockholder proposal advocating for an independent board chairman was not approved, reflecting a preference for the current board structure. Overall, the results signal a positive shareholder sentiment regarding the company's governance and financial oversight.

Quest Diagnostics Incorporated (DGX) has announced the issuance of $500 million in aggregate principal amount of 5.000% senior notes due 2036. This offering, detailed under Item 1.01 of their Form 8-K filed on May 8, 2026, represents a significant debt financing event for the company. The notes will mature on June 30, 2036, and will bear interest payable semi-annually. These senior unsecured notes rank equally with existing and future senior unsecured obligations of Quest Diagnostics. The issuance is governed by an indenture, which includes covenants restricting the company and certain subsidiaries from creating specific liens and entering into certain sale and leaseback transactions. Additionally, limitations are placed on the company's ability to consolidate, merge, or transfer substantially all of its assets. In the event of a change of control triggering event, Quest Diagnostics will be obligated to offer to repurchase the notes at 101% of their principal amount plus accrued interest.

Quest Diagnostics Incorporated (DGX) has announced the pricing of a $500 million public offering of 5.000% senior notes due 2036. This offering, conducted under the company's shelf registration statement, is set to close on May 6, 2026, with net proceeds intended for general corporate purposes. A significant portion of these proceeds may be used to repay existing indebtedness, specifically the $500 million aggregate principal amount of 3.45% Senior Notes maturing on June 1, 2026. This proactive debt management strategy aims to refinance maturing debt with new, longer-term notes. Investors should note the timing of the offering's closing just ahead of the maturity date of the existing notes. The company has also entered into an underwriting agreement with major financial institutions, including Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Mizuho Securities USA LLC, for this transaction.

Quest Diagnostics Inc. reported a strong first quarter for 2026, with net revenues increasing by 9.2% to $2.9 billion, driven primarily by a robust 9.4% growth in its Diagnostic Information Services (DIS) segment. This growth was fueled by a significant 10.9% increase in requisition volume, bolstered by new relationships with Corewell Health and expanded services at Fresenius Medical Care facilities, although revenue per requisition saw a slight decrease due to the business mix of these new partnerships. Diluted earnings per share also saw a healthy rise to $2.24, up from $1.94 in the prior year period, reflecting improved operational performance and cost management. The company also demonstrated solid cash flow generation, with net cash provided by operating activities at $278 million. Financially, Quest Diagnostics maintained a solid position, with total assets growing to $16.7 billion and total stockholders' equity increasing to $7.7 billion. The company's Invigorate program continues to be a focus, aiming for annual cost savings and productivity improvements, which are helping to offset inflationary pressures. Despite some charges related to restructuring and fair value adjustments of contingent considerations, the overall financial health appears robust, supported by continued strategic investments and a substantial share repurchase authorization.

Quest Diagnostics Incorporated (DGX) filed an 8-K on April 21, 2026, to report its financial results for the quarter ended March 31, 2026. The primary purpose of this filing is to provide investors with the company's performance during the first quarter of 2026, as detailed in an attached press release. While the filing itself is procedural, referencing the press release (Exhibit 99.1) is crucial for understanding key financial metrics, revenue performance, profitability, and any forward-looking statements or guidance provided by the company. Investors should review the press release to assess the company's operational execution and its implications for future financial health and stock valuation.

Quest Diagnostics Incorporated (DGX) has announced a significant addition to its Board of Directors through the election of Timothy Wentworth, formerly the chief executive officer of Walgreens Boots Alliance. This appointment, effective March 9, 2026, brings a seasoned executive with extensive experience in the healthcare and retail pharmacy sectors to the company's leadership. Mr. Wentworth has been appointed to serve on the Board's Compensation and Leadership Development Committee and the Quality and Compliance Committee, signaling a focus on critical governance areas. His designation as an independent director, confirmed by both New York Stock Exchange standards and the Company's own guidelines, suggests alignment with best practices in corporate governance. Investors may view this as a positive step towards enhancing board expertise and oversight.

Quest Diagnostics, Inc. (DGX) presented its 2025 fiscal year results in its latest 10-K filing, showcasing its established position in the diagnostic information services market. The company emphasizes its strategy centered on growth and operational efficiency, driven by an industry-leading test menu, collaborations with healthcare providers, leveraging data for population health and value-based care, and adopting innovative technologies like AI and automation. Quest Diagnostics serves a significant portion of the U.S. population, from physicians and hospitals to individual patients, aiming to provide high-quality, convenient, and affordable diagnostic insights. Strategically, Quest Diagnostics continues to focus on its primary customer channels and is expanding its Advanced Diagnostics offerings, including in oncology and neurology. The company has a robust capital deployment framework that includes reinvestment in the business, dividends, and share repurchases, reflecting a commitment to returning value to shareholders. Significant investments in technology, such as AI and a multi-year project to modernize "Order to Cash" processes (Project Nova), are underway to enhance efficiency and customer experience. The company's strong relationships with health plans and extensive network of assets and capabilities position it well within the evolving U.S. healthcare landscape.

Quest Diagnostics Incorporated (DGX) has filed an 8-K report on February 10, 2026, detailing its financial results for the fiscal year and fourth quarter ended December 31, 2025, and announcing significant capital return initiatives. While specific financial figures from the press release are not detailed in this extract, the filing indicates that the company is sharing its operational and financial performance with investors. This update is crucial for understanding the company's recent performance and outlook. The accompanying press releases, incorporated by reference, contain the detailed financial outcomes that investors should review for a comprehensive understanding. Beyond the financial results, Quest Diagnostics is demonstrating a strong commitment to shareholder returns. The Board of Directors has authorized an additional $1 billion for common stock repurchases, signaling confidence in the company's valuation and financial health. Furthermore, the quarterly dividend has been increased by 7.5% from $0.80 to $0.86 per share, effective for the dividend payable in April 2026. This enhanced return to shareholders, combined with the share repurchase program, suggests a positive financial trajectory and a focus on enhancing shareholder value.

Quest Diagnostics Incorporated (DGX) filed an 8-K on January 12, 2026, to disclose their participation in the 44th Annual J.P. Morgan Healthcare Conference. The primary purpose of this filing is to furnish the presentation materials that management will use during their discussion of the Company's strategy, performance, and current market trends. While this filing does not contain new financial results or operational updates, investors should note that the accompanying presentation materials (Exhibit 99.1) are incorporated by reference. These materials may contain forward-looking statements regarding management's current outlook, projections, and expectations. Investors are cautioned to review these statements alongside the risks and uncertainties detailed in Quest Diagnostics' other SEC filings, including their most recent 10-K and 10-Q reports, as actual results could materially differ.

Quest Diagnostics Incorporated (DGX) has filed an 8-K report on October 21, 2025, disclosing its financial results for the quarter ended September 30, 2025. The press release, incorporated by reference, provides key operational and financial performance metrics. Investors should pay close attention to the details within this press release for a comprehensive understanding of the company's recent performance and its implications for future financial health and strategic direction. While the 8-K itself is brief and primarily serves to attach the press release, the substance of the filing lies within the attached document. This includes crucial information regarding revenue, profitability, earnings per share, and any significant business developments or outlooks provided by management. Investors are encouraged to review Exhibit 99.1 for a detailed breakdown of the quarterly performance and any forward-looking statements.

Quest Diagnostics reported solid financial performance for the nine months ended September 30, 2025, with net revenues increasing by 13.5% to $8.2 billion, driven significantly by acquisitions and organic growth within its Diagnostic Information Services (DIS) segment. Net income attributable to Quest Diagnostics grew by 15.0% to $747 million, and diluted earnings per share (EPS) rose by 14.5% to $6.57. The company generated substantial operating cash flow of $1.4 billion, reflecting improved operational efficiency and the positive impact of the CARES Act payroll tax credit. Strategic investments continue, including capital expenditures and the ongoing 'Invigorate' program aimed at cost savings and productivity improvements. While the company experienced increased interest expenses due to recent debt issuance and higher operating costs, including wages and supplies, these were largely offset by revenue growth and cost-saving initiatives. Management remains focused on navigating potential impacts from new healthcare legislation like the OBBBA and the expiration of enhanced premium tax credits, though current estimates suggest a minimal impact on near-term revenues. The company also actively managed its capital structure through debt repayments and share repurchases, demonstrating a commitment to shareholder returns and financial flexibility.

Quest Diagnostics Inc. reported strong financial performance for the second quarter and first six months of 2025, with net revenues increasing significantly year-over-year, primarily driven by its Diagnostic Information Services (DIS) segment. This growth was fueled by a substantial increase in requisition volume, largely attributed to recent acquisitions, alongside positive organic growth. The company also saw an increase in revenue per requisition on an organic basis, indicating improving test mix and utilization. Profitability also showed a marked improvement, with operating income and net income attributable to Quest Diagnostics rising considerably. This was supported by effective cost management, including savings from the 'Invigorate' program, though partially offset by increased costs associated with acquisitions and wage inflation. The company continues to manage its capital structure prudently, with healthy cash flow from operations and significant available borrowing capacity. Looking ahead, Quest Diagnostics is navigating evolving healthcare legislation, such as the One Big Beautiful Bill Act, and currently anticipates a minimal material impact on its consolidated revenues in the near term.

Quest Diagnostics Incorporated (DGX) has filed an 8-K report on July 22, 2025, to disclose its financial results for the quarter ended June 30, 2025. The primary driver of this filing is the accompanying press release (Exhibit 99.1), which details the company's performance and financial condition. Investors should closely examine this press release for specific figures related to revenue, profitability, and any forward-looking statements or guidance provided by the company for the upcoming periods. While the 8-K itself is procedural, the substance lies within the attached press release. Key metrics such as earnings per share (EPS), revenue growth, and operating margins will be crucial for assessing Quest Diagnostics' operational success and its position within the competitive laboratory testing market. Any significant deviations from prior periods or analyst expectations, whether positive or negative, will likely impact the stock's valuation and investor sentiment.

Quest Diagnostics Inc. (DGX) filed an 8-K on May 22, 2025, reporting the voting results from its 2025 Annual Meeting of Stockholders held on May 15, 2025. The filing confirms the election of all nominated directors to serve until the 2026 Annual Meeting, with overwhelming support from shareholders. Additionally, the advisory resolution on executive compensation was approved, reflecting shareholder confidence in the company's pay practices. The appointment of PricewaterhouseCoopers as the independent registered public accounting firm for 2025 also received strong ratification from stockholders. Notably, a stockholder proposal seeking the ability to call a special meeting did not pass, indicating that current governance structures remain favored by the majority. Overall, the results suggest a stable shareholder base supportive of current management and board leadership.

Quest Diagnostics Inc. (DGX) reported its first quarter 2025 results with a notable increase in net revenues, primarily driven by recent acquisitions and organic growth within its Diagnostic Information Services (DIS) segment. Net revenues grew by 12.1% year-over-year, reaching $2.65 billion. The company demonstrated improved operating income and net income, with diluted earnings per share (EPS) rising to $1.94 from $1.72 in the prior year's quarter. Cash flow from operations saw a significant increase, highlighting improved working capital management and higher operating income. While the company repaid $600 million in senior notes, it also utilized its secured receivables credit facility for new borrowings. Management remains confident in the company's liquidity and ability to fund future operations, capital expenditures, and growth initiatives.

Quest Diagnostics Incorporated (DGX) has filed an 8-K report on April 22, 2025, to announce its financial and operational results for the quarter ended March 31, 2025. The primary driver of this filing is the accompanying press release (Exhibit 99.1), which details the company's performance during the period. Investors should review this press release for specific financial metrics, including revenue, profitability, and any forward-looking guidance or commentary provided by management. While the 8-K itself is a procedural document incorporating the press release, the press release contains the substance of the company's quarterly update. Key information investors will likely seek includes year-over-year and sequential performance trends, an understanding of the drivers behind these trends (e.g., volume, pricing, service mix), and any strategic initiatives or challenges that may impact future results. This filing serves as the official channel for disseminating these critical quarterly updates.

Quest Diagnostics Incorporated (DGX) filed an 8-K on March 19, 2025, to disclose information presented at its Investor Day. During this event, the company's leadership team outlined strategies aimed at fostering sustainable growth and enhancing long-term shareholder value. The detailed presentation materials, furnished as exhibits to this filing, provide insights into the company's strategic vision and future outlook. While this filing does not contain new financial results or material business changes, it serves as a communication channel for management's perspectives on the company's direction. Investors are encouraged to review the provided presentation materials for a deeper understanding of Quest Diagnostics' plans, particularly concerning its growth initiatives and how it intends to deliver value to its shareholders. The company also included standard cautionary language regarding forward-looking statements and the inherent risks and uncertainties associated with its business.

Quest Diagnostics Incorporated (DGX) filed an 8-K on March 19, 2025, to announce its Investor Day event. During this event, the company's leadership team is set to discuss strategies aimed at fostering sustainable growth and enhancing long-term shareholder value. A key component of this announcement is the issuance of a press release that reiterates previously provided guidance for the full-year 2025 and outlines the company's outlook beyond 2025. Investors should note that the press release and presentation materials, furnished as exhibits, contain forward-looking statements. While these provide insight into management's current expectations and long-term vision, they are subject to risks and uncertainties that could materially impact actual results. The company has referenced its SEC filings, including its most recent 10-K, for a comprehensive discussion of these potential risks.

Quest Diagnostics Incorporated (DGX) reported fiscal year 2024 revenues of $9.9 billion. The company operates as a leading provider of diagnostic information services, serving approximately one-third of the adult U.S. population annually. Their strategy focuses on growth and operational efficiency, driven by an industry-leading test menu, collaborations with healthcare providers, leveraging data assets for population health, and embracing innovative technologies like AI and automation. Significant strategic initiatives include expanding Advanced Diagnostics™ capabilities, particularly in molecular genomics and oncology, exemplified by the acquisition of Haystack Oncology. Quest Diagnostics also emphasizes consumer-centric services through platforms like QuestHealth.com and aims to partner with hospitals to improve laboratory operations. The company actively manages capital through acquisitions, dividends, and share repurchases, demonstrating a commitment to returning value to stockholders. They also highlight a strong focus on quality improvement, operational efficiency through programs like 'Invigorate', and maintaining strong relationships with health plans and other payers.

Quest Diagnostics Incorporated (DGX) filed an 8-K on January 30, 2025, to report its financial and operational updates. The filing primarily references a press release containing the company's results for the fourth quarter and full year ended December 31, 2024. While specific financial figures from the press release are not detailed within the 8-K itself, this release is a key source of information for investors assessing the company's recent performance. The 8-K also highlights a significant capital return initiative, signaling confidence in the company's financial health and commitment to shareholder value.

Quest Diagnostics Incorporated (DGX) reported its third-quarter and year-to-date financial results for the period ending September 30, 2024. The company demonstrated revenue growth, primarily driven by its Diagnostic Information Services (DIS) segment, which saw an 8.5% increase in net revenues for the quarter, largely due to organic growth and strategic acquisitions. Despite revenue improvements, operating income saw a slight decrease compared to the prior year, impacted by increased costs in services and selling, general, and administrative expenses. Significant strategic acquisitions, including LifeLabs and several other asset acquisitions, were completed during the period, bolstering the company's market position and contributing to revenue and volume growth. However, these acquisitions, along with restructuring efforts under the "Invigorate" program, also led to increased operational costs and integration expenses. The company also successfully raised significant capital through a senior notes offering to fund these strategic initiatives. Investors should note the continued focus on integration and cost management to translate top-line growth into bottom-line profitability.

Quest Diagnostics Incorporated (DGX) filed an 8-K on October 22, 2024, to report its financial results for the quarter ended September 30, 2024. The primary purpose of this filing is to furnish the accompanying press release, which contains the company's operational and financial performance for the specified period. Investors should refer to the press release (Exhibit 99.1) for detailed financial figures, including revenue, profitability, and any forward-looking statements or guidance provided by management. While the 8-K itself is a brief announcement, the attached press release is where the substantive details lie. Investors are encouraged to review this document to understand Quest Diagnostics' performance in the third quarter of 2024, assess trends, and evaluate the company's current financial health and future outlook. The filing indicates that the company is adhering to its reporting obligations by promptly disseminating this information to the public.

Quest Diagnostics Incorporated (DGX) announced the closing of its acquisition of LifeLabs Inc. on August 26, 2024. This strategic move, previously disclosed on July 3, 2024, involves acquiring a Canadian company that offers laboratory diagnostic information and digital health connectivity systems. The acquisition is expected to expand Quest Diagnostics' geographic footprint and service offerings within the Canadian market, potentially enhancing its competitive position and revenue streams in the long term. Investors should note that this filing primarily serves to confirm the closing of the transaction. Further details regarding the financial implications and integration of LifeLabs into Quest Diagnostics' operations will likely be provided in future filings or investor communications. The company has filed the press release regarding this announcement as an exhibit to this report, which may offer additional context.

Quest Diagnostics Incorporated (DGX) has filed an 8-K report detailing the issuance of a substantial amount of senior unsecured notes across three tranches, totaling $1.85 billion. These notes include $400 million due 2027 at 4.600%, $600 million due 2029 at 4.625%, and $850 million due 2034 at 5.000%. The proceeds from this offering are likely intended to fund ongoing strategic initiatives, including a previously disclosed acquisition. This significant debt issuance warrants investor attention regarding the company's leverage profile and capital structure. The filing also notes that the 2027 and 2029 notes will be subject to redemption at 101% of their principal amount if the previously announced acquisition of LifeLabs, Inc. is not consummated by a specified deadline or if Quest Diagnostics decides not to proceed with the acquisition. The 2034 notes, however, will remain outstanding regardless of the acquisition's outcome. Additionally, the company has amended its By-Laws to provide exculpation for officers, aligning with prior stockholder approvals.

Quest Diagnostics Inc. reported solid financial results for the second quarter and first half of 2024. While net income attributable to Quest Diagnostics saw a slight decrease compared to the prior year periods, this was largely influenced by factors such as increased amortization, restructuring costs, and changes in the carrying value of strategic investments. However, the core Diagnostic Information Services (DIS) business demonstrated resilience, with net revenues growing by 2.8% for the quarter and 2.3% for the half-year. This growth was primarily driven by an increase in base business volume and revenue per requisition, as the company continues to reduce its reliance on COVID-19 testing. The company is actively pursuing strategic growth through acquisitions, having completed two acquisitions in the first half of 2024, and announced a significant agreement to acquire LifeLabs Inc. in Canada. Quest Diagnostics is also focused on internal efficiency improvements through its "Invigorate Program," aiming for 3% annual cost savings. Despite a challenging operating environment with inflationary pressures and reimbursement challenges, the company maintained a strong liquidity position and reaffirmed its commitment to returning capital to shareholders through dividends and share repurchases, with a substantial amount still available under its repurchase authorization.

Quest Diagnostics Incorporated (DGX) filed an 8-K on July 23, 2024, to announce its financial results for the quarter ended June 30, 2024. The core of this filing is the attached press release (Exhibit 99.1), which provides the company's performance update for the period. Investors should refer to this press release for detailed financial figures, operational performance, and any forward-looking statements or guidance provided by the company. While the 8-K itself is a formal notification of the earnings release, the actual substance of the financial results, including revenue, profitability, and key performance indicators, will be found within the incorporated press release. Investors are encouraged to review Exhibit 99.1 for a comprehensive understanding of Quest Diagnostics' recent financial condition and operational outcomes.

Quest Diagnostics Incorporated (DGX) has announced a significant strategic move through an Equity Purchase Agreement to acquire LifeLabs Inc. and BPC LP. This transaction, valued at approximately CAD 1.35 billion (USD 985 million) including net debt, involves purchasing all shares and partnership interests of the Canadian diagnostic information and digital health connectivity providers. The acquisition is expected to be completed by the end of 2024, subject to customary closing conditions, including regulatory approvals under the Competition Act (Canada) and the Investment Canada Act, as well as consents from key customers. This move represents a material expansion for Quest Diagnostics into the Canadian market, aiming to enhance its service offerings and market presence. Investors should monitor the satisfaction of the closing conditions, as failure to obtain necessary approvals could result in a termination fee for Quest Diagnostics. The company has also entered into restrictive covenants regarding the operations of the Target Entities during the interim period, underscoring the definitive nature of the agreement.

Quest Diagnostics Inc. (DGX) filed an 8-K on May 21, 2024, reporting on outcomes from its Annual Meeting of Stockholders held on May 16, 2024. Key among these outcomes is the approval by stockholders of an amendment to the Company's Restated Certificate of Incorporation. This amendment allows for the exculpation of officers, a measure permitted by Delaware law, designed to shield officers from personal liability for certain breaches of fiduciary duty. This change was officially filed with the Secretary of State of Delaware on May 20, 2024. Additionally, the filing details the voting results for director elections, executive compensation approval, and the ratification of PricewaterhouseCoopers as the independent auditor. While director elections and auditor ratification passed with strong support, the advisory vote on executive compensation was also approved. Notably, a stockholder proposal concerning climate risk management was not approved, indicating differing views on the urgency or approach to setting science-based targets and transition planning.

Quest Diagnostics Incorporated (DGX) announced the appointment of Robert B. Carter to its Board of Directors, effective May 16, 2024. Mr. Carter brings significant executive experience, currently serving as Executive Vice President and Chief Information Officer at FedEx Corporation, and Co-President and Co-CEO of FedEx Services. His addition to the Board is expected to enhance the company's strategic oversight and digital transformation efforts, given his extensive background in technology and corporate leadership. The Board has determined that Mr. Carter meets the independence criteria set forth by the New York Stock Exchange and the Company's own governance guidelines. His appointment as a non-employee director means he will be compensated according to the company's standard practices for its non-employee directors. Further details regarding committee assignments are pending.

Quest Diagnostics Incorporated (DGX) reported its first quarter 2024 results, showing a modest increase in net revenues driven by its core Diagnostic Information Services (DIS) segment. Despite a slight overall revenue growth of 1.5% to $2.37 billion, operating income saw a marginal decline of 1.7% to $300 million, and net income attributable to Quest Diagnostics decreased by 3.9% to $194 million. This was reflected in diluted earnings per share, which fell to $1.72 from $1.78 in the prior year's comparable quarter. The company completed an acquisition of Lenco Diagnostic Laboratories for $111 million, contributing to the growth in its DIS segment, although overall revenue per requisition saw minimal change. Management highlighted the ongoing 'Invigorate' program aimed at driving cost savings and productivity improvements, which is being leveraged to offset inflationary pressures and reimbursement challenges. Looking ahead, Quest Diagnostics maintains a strong liquidity position with significant borrowing capacity available.

Quest Diagnostics Incorporated (DGX) filed an 8-K on April 23, 2024, to report its financial results for the quarter ended March 31, 2024. The primary purpose of this filing is to provide investors with early access to the company's performance data as announced in their press release, which is incorporated by reference. Investors should review the press release (Exhibit 99.1) for detailed financial metrics, operational performance, and any forward-looking statements or guidance provided by the company. While the 8-K itself does not contain the detailed financial statements, it serves as a formal notification of the release of this information. Key details regarding revenue, earnings per share, segment performance, and any management commentary on business trends or strategic initiatives would be found within the accompanying press release. Investors interested in the company's immediate financial standing and outlook should consult this exhibit.

Quest Diagnostics Incorporated (DGX) operates as a leading provider of diagnostic information services, serving approximately one-third of the adult U.S. population annually. The company's strategy focuses on growth and operational efficiency through customer-centric solutions, an extensive test menu, data utilization for population health, and technological innovation, including AI. Quest Diagnostics aims to meet the evolving needs of physicians, hospitals, and consumers by offering high-quality, innovative, convenient, and affordable services across its broad network. The company emphasizes continuous quality improvement and operational efficiency, driven by initiatives like the Quest Management System and Invigorate program. Strategic acquisitions are a key component of their growth strategy, alongside a commitment to returning capital to shareholders through dividends and share repurchases. Quest Diagnostics is navigating a dynamic healthcare landscape characterized by evolving reimbursement models, increasing consumer engagement, and technological advancements, while maintaining a strong focus on compliance and risk management.

Quest Diagnostics Incorporated (DGX) filed an 8-K on February 1, 2024, primarily detailing its fourth quarter and full-year 2023 financial results and a significant capital return to shareholders. While the full financial details are in the referenced press release, the key takeaway for investors is the board's authorization of a 5.6% increase in the quarterly dividend, raising it to $0.75 per share ($3.00 annually). This marks the 13th consecutive year of dividend increases, underscoring the company's commitment to shareholder returns and financial stability. Investors should also note the announcement of the Q4 and FY 2023 results, which are incorporated by reference. While specific figures are not detailed within the 8-K text provided, this filing serves as the official notification of these results. The dividend increase, in particular, signals management's confidence in the company's ongoing performance and ability to generate sufficient cash flow to reward its shareholders.

Quest Diagnostics Incorporated (DGX) has filed a Form 8-K to report on the issuance of $750 million aggregate principal amount of 6.400% senior notes due 2033. This debt offering, priced on October 30, 2023, and issued on November 1, 2023, aims to raise capital for the company. The notes are senior unsecured obligations and will rank equally with existing and future senior unsecured debt. The issuance was conducted under the company's shelf registration statement and involved an underwriting agreement with several prominent financial institutions. This filing indicates a strategic move by Quest Diagnostics to secure long-term financing. Investors should note the coupon rate of 6.400% and the maturity date of November 30, 2033. The indenture includes covenants that may restrict certain actions by the company and its subsidiaries, such as creating liens or engaging in sale and leaseback transactions, and also contains provisions for a mandatory repurchase offer at 101% of principal in the event of a change of control triggering event.

Quest Diagnostics Incorporated (DGX) reported its third quarter and year-to-date results for the period ending September 30, 2023. Overall revenue for the quarter decreased by 7.7% to $2.3 billion, and for the nine-month period, it declined by 7.8% to $7.0 billion, primarily due to a significant reduction in COVID-19 testing revenues. The core "base business" excluding COVID-19 testing showed resilience, with revenue and volume increasing year-over-year for both periods. Despite revenue headwinds, the company managed its costs effectively, with operating income decreasing at a slower pace than revenues. Diluted earnings per share for the third quarter were $1.96, down from $2.17 in the prior year. Net income attributable to Quest Diagnostics for the quarter was $225 million, a decrease from $256 million in the same period last year. The company continued to make strategic investments, including significant acquisitions, and maintained its commitment to returning capital to shareholders through dividends and share repurchases, although no shares were repurchased in the nine months ended September 30, 2023, compared to substantial repurchases in the prior year.

Quest Diagnostics Incorporated (DGX) filed an 8-K on October 24, 2023, to announce its financial results for the quarter ended September 30, 2023. The filing primarily consists of a press release detailing these results. Investors should refer to the attached press release (Exhibit 99.1) for specific financial and operational performance metrics. This 8-K serves as the official notification of the company's performance during the third quarter of 2023. While the 8-K itself doesn't contain the detailed analysis, it directs stakeholders to the press release for the core information. Investors interested in understanding Quest Diagnostics' performance, including revenue, profitability, and any forward-looking statements or guidance, will need to examine the content of Exhibit 99.1. This filing is a standard procedure for publicly traded companies to promptly disclose material financial information.

This 8-K filing from Quest Diagnostics Incorporated (DGX) reports a change in its Board of Directors. Dr. Gail R. Wilensky has decided not to seek re-election at the upcoming 2024 Annual Stockholders Meeting and will retire from the Board at that time, upon the expiration of her current term. This is a voluntary decision by Dr. Wilensky, not a result of any disagreement with the Company. While the departure of a board member can sometimes signal strategic shifts or governance considerations, the filing indicates this is a planned retirement upon the conclusion of her term. Investors should note this change but recognize it as a standard transition unless further information is provided by the company regarding the reasons for her decision or any replacement appointments. The effective date of her retirement is tied to the 2024 Annual Stockholders Meeting, expected in May 2024.

Quest Diagnostics Inc. (DGX) reported its second-quarter and first-half financial results for the period ending June 30, 2023. For the quarter, net revenues were $2.34 billion, a slight decrease of 4.7% year-over-year, impacted by a significant decline in COVID-19 testing revenues, though this was partially offset by growth in the base business and recent acquisitions. Diluted earnings per share (EPS) were $2.05, an increase of 4.6% compared to the prior year, showcasing improved profitability on a per-share basis despite lower overall revenues. For the first six months of the year, net revenues declined by 7.8% to $4.67 billion, primarily due to the ongoing normalization of COVID-19 testing volumes. However, the company's core diagnostic information services (DIS) business saw strong growth in its base operations. The company also made significant strategic acquisitions, including that of Haystack Oncology, Inc., and continued its Invigorate program aimed at cost structure improvement and performance enhancement. Despite a decrease in net cash from operating activities, the company maintained a strong liquidity position and reaffirmed its commitment to returning capital to shareholders through dividends and an active share repurchase program.

Quest Diagnostics Incorporated (DGX) filed an 8-K on July 26, 2023, primarily to report its financial results for the quarter ended June 30, 2023. While the filing itself is brief, it directs investors to an attached press release (Exhibit 99.1) for detailed operational and financial performance information. Investors should review this press release for specific figures related to revenue, earnings, and any forward-looking statements or guidance provided by the company. The core purpose of this filing is to ensure public disclosure of material financial information in a timely manner. Investors relying on this report should understand that the 8-K serves as a notification and incorporation by reference to the more comprehensive earnings announcement. Therefore, the real substance of the company's quarterly performance, management's commentary, and future outlook will be found within the press release itself, which is considered an integral part of this filing.

This 8-K filing from Quest Diagnostics Inc. (DGX) details the voting results from their Annual Meeting of Stockholders held on May 17, 2023. Key outcomes include the overwhelming re-election of all director nominees, indicating strong shareholder confidence in the current board leadership. The advisory resolution to approve executive compensation was also approved, though with a notable percentage of opposition, suggesting some shareholders may have reservations regarding pay practices. Furthermore, shareholders voted to ratify the appointment of PricewaterhouseCoopers as the independent auditor, ensuring continued oversight of financial reporting.

Quest Diagnostics reported its first-quarter 2023 financial results, showing a decrease in net revenues and net income compared to the prior year. This decline was primarily driven by a significant reduction in COVID-19 testing volumes, which had a substantial impact on overall revenue and profitability. Despite the top-line decrease, the company highlighted growth in its "base business" revenue, excluding COVID-19 testing, indicating resilience in its core operations. The company also provided an update on its strategic initiatives, including the "Invigorate" program aimed at cost structure improvement. Management discussed ongoing investments in acquisitions, such as the recent purchase of New York-Presbyterian's laboratory assets and the planned acquisition of Haystack Oncology, signaling a continued focus on strategic growth and expanding service offerings in specialized areas like oncology. Investors should monitor the integration of these acquisitions and the continued growth of the base business as key indicators of future performance.

Quest Diagnostics Incorporated (DGX) filed an 8-K on April 27, 2023, announcing both its first-quarter 2023 financial results and a significant strategic acquisition. The company reported its financial performance for the quarter ended March 31, 2023, details of which are available in an attached press release. This announcement provides investors with an update on the company's operational and financial standing at the beginning of the fiscal year. In addition to the financial results, Quest Diagnostics also revealed its definitive agreement to acquire Haystack Oncology, Inc. This move signifies a strategic expansion into the rapidly growing field of minimal residual disease (MRD) testing within oncology. The acquisition is expected to enhance the company's capabilities in precision oncology and represents a key growth initiative for Quest Diagnostics, aiming to capture opportunities in advanced diagnostic services.

Quest Diagnostics Incorporated (DGX) filed an 8-K on March 17, 2023, primarily to disclose information presented at their Investor Day held on March 16, 2023. During this event, management provided an updated perspective on the U.S. laboratory market, the company's strategic direction, capital allocation priorities, and long-term financial outlook. Key takeaways include the reiteration of previously issued full-year 2023 guidance and an updated outlook spanning the 2023 to 2026 period. Investors should note that the detailed information, including a press release and presentation materials, is furnished as an exhibit to this 8-K. While this filing does not typically involve new financial statements, the provided materials offer insights into management's expectations and strategic plans. Investors are encouraged to review these exhibits for a comprehensive understanding of the company's forward-looking statements and the associated risks and uncertainties, which are further detailed in Quest Diagnostics' other SEC filings.

Quest Diagnostics Incorporated (DGX) announced a significant leadership transition through a press release filed on March 7, 2023, related to events on March 3, 2023. The Board of Directors has elected James E. Davis, the current Chief Executive Officer and President, to also assume the role of Chairman of the Board, effective April 1, 2023. This move consolidates leadership under Mr. Davis, who has been CEO and President since October 1, 2021. He will succeed Stephen H. Rusckowski, who has held the Chairman position since January 1, 2017. Investors should view this as a signal of continued strategic direction under Mr. Davis's leadership, potentially indicating a focus on executing current growth initiatives and operational efficiencies without immediate disruption from a new external leadership perspective. The separation of CEO and Chairman roles is a common governance practice, and their consolidation can sometimes streamline decision-making, though it is important to monitor board independence going forward.

Quest Diagnostics Incorporated, a leading provider of diagnostic information services, reported $9.9 billion in net revenues for 2022. The company's strategy centers on accelerating growth through acquisitions, capitalizing on health plan access, increasing share with Integrated Delivery Networks (IDNs), growing its Advanced Diagnostics offerings, and building consumer-initiated testing. Quest Diagnostics emphasizes operational excellence, innovation in areas like molecular diagnostics and precision medicine, and a strong focus on customer experience. The company highlighted its pivotal role in the COVID-19 pandemic response, performing approximately 77 million tests. Looking forward, Quest Diagnostics is focused on driving efficiency through automation and digital transformation, while also maintaining a disciplined capital deployment framework including dividends and share repurchases. The company operates in a dynamic healthcare landscape and navigates competitive pressures and evolving regulatory environments.

Quest Diagnostics Inc. (DGX) filed an 8-K on February 2, 2023, detailing key financial and shareholder return actions. The company announced its financial results for the fourth quarter and full year ended December 31, 2022. While specific figures from the earnings release are not detailed in the 8-K itself, this filing serves as the official notification of their release, directing investors to Exhibit 99.1 for comprehensive performance data. Beyond earnings, the report highlights significant capital allocation decisions aimed at enhancing shareholder value. Quest Diagnostics' Board of Directors authorized an additional $1 billion for common stock repurchases, underscoring management's confidence in the company's stock and its commitment to returning capital to shareholders. Furthermore, the quarterly dividend was increased from $0.66 to $0.71 per share, marking the twelfth dividend increase since 2011, indicating a consistent track record of dividend growth.

Quest Diagnostics Incorporated (DGX) filed an 8-K on November 18, 2022, primarily detailing changes related to its executive team and corporate governance. The company announced the appointment of four new executive officers: Mark E. Delaney, Mark A. Gardner, Karthik Kuppusamy, and Patrick T. Plewman. These individuals have been elevated to executive officer roles and will participate in the company's Executive Officer Severance Plan, indicating a formalization of their roles and associated benefits. Additionally, Quest Diagnostics amended and restated its By-Laws, effective November 14, 2022. These revisions specifically address director nominations and proxy solicitations, including updates for compliance with Rule 14a-19 under the Securities Exchange Act of 1934. While these changes are largely procedural and clarifying, they signal the company's commitment to adhering to updated regulatory requirements and best practices in corporate governance.

Quest Diagnostics Inc. (DGX) announced significant leadership changes effective November 1, 2022. The company's Board of Directors has appointed James E. Davis as the new Chief Executive Officer and President, taking over these roles from Stephen H. Rusckowski, who will continue to serve as Chairman of the Board. This transition marks a key moment for the company's strategic direction and operational leadership. Furthermore, the Board also increased its size from 9 to 10 directors and elected Mr. Davis to fill the newly created vacancy. These changes, detailed in an 8-K filing dated November 1, 2022, are accompanied by a press release (Exhibit 99.1) providing further context on this executive transition. Investors should monitor Mr. Davis's initial strategies and priorities as the new CEO.